TaiRx Inc is a Taiwan-based company mainly engaged in the development and research of new drugs. The Company primarily focus on the research and development of cancer treatment drugs and sepsis adjuvant therapy drugs. The Company's main products include CVM-1118, Rexis, Zelnite, TRX-NOC, TRX-920, TRX-711, TRX-105 and others. CVM-1118 and Rexis are in clinical trials, and Zelnite drugs are sold to domestic medical institutions at all levels through distributors.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/08/26	NT$13.00	-0.38%	20,004
14/08/26	NT$13.05	-1.88%	46,170
13/08/26	NT$13.30	-1.48%	31,338
12/08/26	NT$13.50	0.00%	44,443
11/08/26	NT$13.50	-0.37%	13,212

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange 17/08/2026			5-day change	1st Jan Change
13.00 ^TWD	-0.38%		-1.89%	-40.64%

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.46B 45.77M 39.51M 37.07M 33.76M 63.48M 4.38B 64.36M 435M 170M 2.19B 172M 168M 7.29B	P/E 2024	-20.5x	P/E 2025	-11x
Enterprise Value	1.13B 35.39M 30.56M 28.67M 26.11M 49.09M 3.38B 49.77M 336M 132M 1.7B 133M 130M 5.64B	EV / Sales 2024	286x	EV / Sales 2025	75.1x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

08-11	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
04-15	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
22/09/25	TaiRx, Inc.(TPEX:6580) dropped from S&P Global BMI Index	CI
14/08/25	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
11/04/25	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
23/09/24	TaiRx, Inc.(TPEX:6580) added to S&P Global BMI Index	CI
11/08/24	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
11/04/24	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
09/08/23	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
11/04/23	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/08/22	TaiRx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
13/04/22	TaiRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	CI
09/08/21	Tairx, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	CI

1 day	-0.38%
1 week	-1.89%
Current month	-1.52%
1 month	+4.00%
3 months	-19.25%
6 months	-35.64%
Current year	-40.64%

TaiRx, Inc. Stock

Stocks

6580

TW0006580004

Biotechnology & Medical Research

Valuation: TaiRx, Inc.

Chart: TaiRx, Inc.

Latest news : TaiRx, Inc.

Press Releases: TaiRx, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: TaiRx, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	12.7	13.65
1 month	11.95	15.5
Current year	11.95	23.45
1 year	11.95	31.8
3 years	11.95	44
5 years	11.95	89.5
10 years	11.95	89.5

Manager	Title	Age	Since
Yi Wen Chu IRC	Investor Relations Contact	-	-
Du Shieng Chien CEO	Chief Executive Officer	-	22/08/2011
Jackson Huang DFI	Director of Finance/CFO	-	05/10/2015

Director	Title	Age	Since
Du Shieng Chien CHM	Chairman	-	22/08/2011
Yi Wen Chu BRD	Director/Board Member	-	18/12/2013
Hsiu Hui Li BRD	Director/Board Member	-	22/08/2011

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TAIRX, INC.	-0.38%	-1.89%	-42.22%	-52.73%	45.73M
LONZA GROUP AG	+0.68%	-2.28%	+1.91%	+19.70%	48.42B
REVOLUTION MEDICINES, INC.	+5.51%	+3.89%	+489.93%	+634.14%	43.66B
BEONE MEDICINES AG	+3.60%	+0.30%	+12.77%	+87.27%	39.51B
IQVIA HOLDINGS INC.	+1.58%	-0.78%	+24.71%	+12.09%	38.95B
CELLTRION, INC.	-0.50%	+0.85%	+20.60%	+58.18%	32.61B
ASCENDIS PHARMA A/S	-0.28%	-2.62%	-	-	16.32B
MEDPACE HOLDINGS, INC.	+2.48%	-1.65%	+27.99%	+133.63%	16.15B
EUROFINS SCIENTIFIC SE	-0.62%	-0.06%	+3.95%	+27.74%	14.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.96%	+3.74%	+83.06%	+43.78%	13.37B
Average	+1.40%	-0.68%	+69.19%	+107.09%	26.32B
Weighted average by Cap.	+1.94%	-0.62%	+102.24%	+152.27%

	2024	2025
Net sales	8.22M 258K 223K 209K 190K 358K 24.69M 363K 2.45M 961K 12.37M 969K 948K 41.14M	27.88M 875K 756K 709K 646K 1.21M 83.69M 1.23M 8.31M 3.26M 41.93M 3.29M 3.22M 139M
Net income	-139M -4.36M -3.76M -3.53M -3.22M -6.05M -417M -6.13M -41.39M -16.22M -209M -16.37M -16.01M -695M	-221M -6.94M -5.99M -5.62M -5.12M -9.63M -664M -9.76M -65.93M -25.83M -333M -26.07M -25.5M -1.11B
Net Debt	-505M -15.85M -13.69M -12.84M -11.69M -21.99M -1.52B -22.29M -151M -58.98M -759M -59.52M -58.23M -2.53B	-330M -10.37M -8.96M -8.4M -7.65M -14.39M -992M -14.59M -98.5M -38.6M -497M -38.95M -38.11M -1.65B